Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
|Articles|June 6, 2016
Shire to Create Up to 200 Jobs at Baxalta Facility
June 06, 2016
Advertisement
Shire plans to retain and expand Baxalta’s drug research outpost in Kendall Square, following its $32 billion purchase of Baxalta Inc., the
The takeover sees Shire employ more than 3,000 workers in Massachusetts, making it the state’s second largest biopharma employer, after Sanofi Genzyme, the Globe adds.
Shire CEO Flemming Ornskov said Shire plans to expand Baxalta’s 400-person research center at Kendall Square by 100 to 200 jobs and keep an office at the research center "as a window on the entrepreneurial activity in the area".
Read the Boston Globe report
Advertisement
Related to this article
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
2
Where GLP-1 Development May be Headed
3
Connecting RWD to Better Understand the Patient Journey
4
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
5